Fairvalue-Calculator Fairvalue-Calculator
EN DE

Meribank Biotech Co (4724) Fair Value & Analysis

Healthcare · TW · Market cap 949M TWD

Price9.95 TWD
Fair Value13.96 TWD
Upside+40.3%
Quality95/100
Evidence: Medium Range 10.30 TWD – 17.62 TWD

Fair value as of: Jun 24, 2026

Analysis

Meribank Biotech Co (4724) currently trades at 9.95 TWD, while our model-based Fair Value estimate is 13.96 TWD — implying the stock looks roughly 40.3% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.

About the company

Meribank Biotech Co., Ltd researches, develops, manufactures, and stores mesenchymal stem cells in Taiwan. The company engages in the detection, extraction, cryopreservation, archiving, and storage of umbilical cord blood, placental and umbilical cord mesenchymal stem cells, adult peripheral blood stem cells, and immune cells. It also provides cell cryopreservation services. The company was founded in 2001 and is based in Taipei, Taiwan.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -84% Regeneron Pharmaceuticals, Inc (REGN) +109% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -64%

Frequently asked questions

Is Meribank Biotech Co (4724) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 13.96 TWD versus a price of 9.95 TWD — about +40% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 4724?
Our 21-model fair value for Meribank Biotech Co is 13.96 TWD (as of Jun 24, 2026), built from audited fundamentals. The current price is 9.95 TWD.
What is the quality score of 4724?
Meribank Biotech Co has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.